SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Business
An Early February Focus on U.S.-Asia Drug Development Deals - UPDATED
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
February 2, 2021
 · 
6 min read
 · 
Heather McKenzie
Drug Development
JPM2021, Day 2: Gilead, Merck, AbbVie, Pfizer and More
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
January 13, 2021
 · 
5 min read
 · 
Mark Terry
Courtesy of Smith Collection/Gado/Getty Images
Business
AbbVie Says Goodbye to Sosei’s Neurological-Focused Muscarinic Agonist Programs
Sosei Group Corporation has announced it is regaining the worldwide rights to its muscarinic agonist programs after AbbVie said it is backing away from the program.
January 5, 2021
 · 
3 min read
 · 
Brandon May
Kate Krav-Rude/Shutterstock
BioMidwest
AbbVie Snatches Up Antibody from Harbour BioMed to Fight COVID-19 and Related Mutations
Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie.
December 15, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
AbbVie’s Hopes of Replacing Humira Sales with Rinvoq Gains Momentum for Ulcerative Colitis
AbbVie announced that its Phase III induction study, U-ACHIEVE, of Rinvoq (upadacitinib) in moderate to severe ulcerative colitis, hit the primary endpoint of clinical remission at week 8.
December 9, 2020
 · 
3 min read
 · 
Mark Terry
JHVEPhoto/Shutterstock
Business
ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.
December 7, 2020
 · 
4 min read
 · 
Mark Terry
Business
Frontier and AbbVie Team Up Against Elusive Protein Targets
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.
December 3, 2020
 · 
3 min read
 · 
Heather McKenzie
Kent Sievers/Shutterstock
Business
Warren Buffett Makes Big Bets on Pharma Stocks
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
November 17, 2020
 · 
2 min read
 · 
Alex Keown
Q3 Reports: AbbVie, BMS, Allogene, Gilead and AstraZeneca
It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
November 5, 2020
 · 
6 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Job Trends
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
January 4, 2022
 · 
5 min read
Job Trends
AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
 · 
1 min read
Deals
Allergan Aesthetics Completes Acquisition of Soliton
December 16, 2021
 · 
4 min read
FDA
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
December 14, 2021
 · 
19 min read
FDA
FDA Approves Allergan’s VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults
December 13, 2021
 · 
1 min read
Business
SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
December 10, 2021
 · 
7 min read
Drug Development
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn’s Disease
December 6, 2021
 · 
20 min read
BioMidwest
AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
December 3, 2021
 · 
13 min read
BioMidwest
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn’s Disease to European Medicines Agency (EMA)
November 30, 2021
 · 
13 min read
BioMidwest
AbbVie to Present at the Evercore ISI Conference - Nov 23, 2021
November 23, 2021
 · 
1 min read
Load More